CA Patent

CA2949932C — Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Assigned to Rhizen Pharmaceuticals AG · Expires 2021-08-10 · 5y expired

What this patent protects

The present invention relates to a crystalline p-toluenesulfonic acid salt of the compound ( see above formula)

USPTO Abstract

The present invention relates to a crystalline p-toluenesulfonic acid salt of the compound ( see above formula)

Drugs covered by this patent

umbralisib-tosylate (UMBRALISIB TOSYLATE)

Patent Metadata

Patent number: CA2949932C
Jurisdiction: CA
Classification: —
Expires: 2021-08-10
Drug substance claim: No
Drug product claim: No
Assignee: Rhizen Pharmaceuticals AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.